Response group:None

3 trials

Sponsors

Shanghai Pulmonary Hospital, Chinese PLA General Hospital, Suqian First Hospital

Conditions

Hepatocellular carcinomaModerate to severe rheumatoid arthritisNon-small cell lung cancer

Early Phase 1

Effect of intestinal microbiome diversity on the efficacy and survival of chemotherapy for advanced non-small cell lung cancer

Active, not recruitingChiCTR1900028186

Shanghai Pulmonary HospitalNon-small cell lung cancer

Start: 2019-12-10Updated: 2019-12-16

Unknown Phase

Response evaluation using contrast-enhanced ultrasound for hepatocellular carcinoma treated with PD-1 antibody plus with lenvatinib therapy: A Prospective Study

RecruitingChiCTR2400094263

Chinese PLA General HospitalHepatocellular carcinoma

Start: 2024-03-15Updated: 2025-01-06

Study on the correlation between adalimumab therapeutic drug monitoring and clinical efficacy in patients with with moderate to severe active rheumatoid arthritis

Active, not recruitingChiCTR2500097416

Suqian First HospitalModerate to severe rheumatoid arthritis

Start: 2025-03-01Updated: 2025-02-24

Related Papers

Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy.

2025-12-01